Short answer
Lilly (Eli) (LLY) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $23.0B (up 47.7% year over year) with net income of $7.1B.
Q2 2026 key financials · XBRL
- Revenue
- $23.0B
- +47.7% YoY · +16.0% QoQ
- Net income
- $7.1B
- +25.3% YoY · −4.1% QoQ
- EPS (diluted)
- $7.93
- +26.1% YoY · −4.0% QoQ
Source: XBRL data from the Lilly (Eli) (LLY) Q2 2026 10-Q on SEC EDGAR. USD.
Lilly (Eli) Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $22,974 million, up 48% YoY from $15,558 million, driven by Mounjaro and Zepbound volume
- Net income $7,095 million, up 25% YoY from $5,661 million
- Mounjaro and Zepbound best-performing products, representing 65% of six-month revenue
- Foundayo launched in U.S.; Bridge Program discounted obesity medicines began July 1, 2026
- Near-term headwinds: pricing pressure, uncertain Medicare uptake, channel dynamics, tariffs, and counterfeit incretins
Risk Factors
- No material changes from December 31, 2025 Form 10-K risk factors
- Regulatory and compliance risks unchanged from the 2025 Form 10-K
- Operational and competitive risks unchanged from the 2025 Form 10-K
- Financial and liquidity risks unchanged from the 2025 Form 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Lilly (Eli) quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.